58 results about "Bone morphogenetic protein 6" patented technology

The invention relates to a cell model obtained after targeted knockout of a rabbit BMP2 gene based on CRISPR/Cas9 and application thereof, belonging to the technical field of molecular biology and biomedicine. According to the invention corresponding oligos are synthesized for three targeting sites of the rabbit BMP2 gene on the design principles of CRISPR/Cas9 and are constructed on px458 vectors; and a CRISPR/Cas9 system is constructed directed at the three targeting sites in rabbit mesenchymal stem cells, and the CRISPR/Cas9 system can effectively knock out the rabbit BMP2 gene, is easy to operate and has high rabbit BMP2 gene knockout efficiency. The cell model disclosed in the invention can greatly promote research related to the functions and signaling pathways of the BMP2 gene.

A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2. BBP increases the over-all osteogenic activity of rgBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.

The present invention relates to an in vitro detection method that whether a sample contains target nucleic acid or not is detected by utilizing fusion protein of split-signaling morphogenetic protein and nucleic acid enzyme defect type Cas9 protein, a kit and a device.

The present invention relates to a therapeutic agent or prophylactic agent for a disease requiring enhancement of bone morphogenetic protein production or promotion of osteogenesis; an agent for enhancement of bone morphogenetic protein production or an agent for promotion of osteogenesis, a food, beverage or feed for enhancement of bone mornhogenetic protein production or promotion of osteogenesis, characterized in that each comprises as an effective ingredient at least one compound selected from the group consisting of (a) an acidic saccharide, (b) a polyacrylic acid, (c) chlorogenic acid and (d) an oxidation processed product of chlorogenic acid, or an extract derived from algae.

The present invention provides modified, highly potent bone morphogenetic proteins. In particular, the present invention relates to the observation that BMP-6 and BMP-9 are less susceptible to inhibition by Noggin that are other members of the BMP subfamily of proteins. The present invention features chimeric bone morphogenetic proteins in which the middle portion of BMP-6 or BMP-9 replaces the middle portion of another BMP subfamily protein to cause resistance to inhibition by Noggin or other Noggin-like antagonists. Other embodiments of modified BMPs, compositions and methods of use are also included.

The present invention provides formulations of cysteine knot proteins, including TGF-β superfamily proteins and bone morphogenic proteins that are pH stabilized. In particular, the present invention relates to the observation that certain buffers enhance the stability of cysteine knot proteins, including TGF-β superfamily proteins and bone morphogenic proteins. In particular, disclosed herein are liquid and lyophilized formulations prepared with a glycylglycine and tartaric acid buffers to stabilize the pH of the formulation.

The present invention relates to an application of bone morphogenetic protein 4 in cancer inhibition. Specifically bone morphogenetic protein (BMP) has a liver cancer stem cell differentiation induction effect, wherein CD133 protein expression of liver cancer cell lines can be down-regulated and liver cancer cell line CD133+ liver cancer stem cell differentiation can be promoted with BMP4, and BMP4 can further be provided for inhibiting in vitro proliferation and self-renewal of liver cancer cell lines and inhibiting tumorigenicity of immune-deficient mice. The present invention further provides BMP4-induced liver cancer stem cell differentiation action mechanism.

Methods are provided for determining cartilage degeneration, regeneration, or aging in a joint tissue in a patient by measuring levels of osteogenic protein-1 (OP-1) protein and/or mRNA in synovial fluid or joint tissue. The methods according to the invention are useful for detecting, diagnosing, predicting, determining a predisposition for, or monitoring joint tissue degeneration, regeneration, or aging in a patient including inflammatory joint disease or age-related disorders.

The invention relates to an inducing method of mesenchymal stem cells. The inducing method includes: obtaining the mesenchymal stem cells for in-vitro culture; using inducing liquid for induction in the process of in-vitro culture, wherein the inducing liquid comprises angiotensin II and bone morphogenetic protein-2. The bone morphogenetic protein capable of promoting growth and differentiation of the mesenchymal stem cells and the angiotensin II capable of promoting proliferation of the mesenchymal stem cells are adopted as inducers to induce culture of the mesenchymal stem cells, so that too-early wall-removal apoptosis of the mesenchymal stem cells can be prevented, and activity of the mesenchymal stem cells can be improved while conversion rate of the same can be increased.

The invention relates to a method for inducing synovium mesenchymal stem cells (SMSCs) to be differentiated to chondrocytes by in-vitro lentivirus mediated BMP-2 (Bone Morphogenetic Protein) genes. The method comprises the following steps of: separating and culturing synovium mesenchymal stem cells; constructing a recombinant plasmid pFUGW-oBMP-2; preparing morbus virosus of transfected lentivirus; and transfecting synovium mesenchymal stem cells by the morbus virosus of transfected lentivirus, wherein in the step of preparing morbus virosus of transfected lentivirus, the transfected lentivirus is jointly formed by the recombinant plasmid pFUGW-oBMP-2 and a packaging plasmid; and in the step of transfecting synovium mesenchymal stem cells by the morbus virosus of transfected lentivirus, synovium mesenchymal stem cells over third generation is taken to be mixed with the morbus virosus of transfected lentivirus, and then added into incomplete chondroblast inducing culture liquid to induce so as to obtain chondrocytes. SMSCs transfected by the transfected lentivirus provided by the invention are safe enough and can be spontaneously differentiated to cartilage in vitro.

The present invention relates to reindeer bone formation inducing protein called bone morphogenetic protein 3c (BMP-3c), nucleotide molecules encoding the protein and host cells expressing the protein. The present invention relates also to the use of said BMP-3c for treating disorders related to bone and cartilage formation. Osteogenic devices and pharmaceutical compositions containing the protein are also disclosed.

A new family of proteins, the SARA proteins, has been identified. These proteins bind to receptor-regulated Smad proteins and modulate signal transduction by TGFβ, activin and bone morphogenetic protein.

The invention relates to the raise livestock field, and discloses a method for predicating milk yield of small tailed han sheep by virtue of BMPR(bone morphogenetic protein receptor )-1B or PRLR (prolactin receptor) gene SNP (single nucleotide polymorphism) lotus. The method comprises the following steps: extracting a small tailed han sheep genome DNA (deoxyribonucleic acid); amplifying a sequence of SNP lotus-containing BMPR-IB A746G or a sequence of SNP lotus-containing PRLR gene; judging an E2-C34T mutant gene type of the BMPR-IB A746G or PRLR gene. The method disclosed by the invention can be applied to carrying out feeding and management according to difference of milk secretion control gene types, and can be used for improving the milk secretion amount, guaranteeing that a lamb has enough milk intake, improving the survival rate and reducing the breeding economic loss. The method disclosed by the invention provides a molecular-level technical support for predicating and molecularly selecting the milk yield of small tailed han sheep; by applying the method disclosed by the invention, the survival rate and development rate of the lambs are greatly improved, so that better breeding economic benefits are produced, and therefore, the method has good application prospect.

The invention belongs to the technical field of medical biology, and particularly relates to an application of an induction method for improving the capacity of mesenchymal stem cells in promoting acute myeloid leukemia cell differentiation. The mesenchymal stem cells provided by the invention are human-derived umbilical cord mesenchymal stem cells (UC-MSCs), and mesenchymal stem cells (pre-activeMSCs) obtained after pretreatment and activation by cytokine bone morphogenetic protein 6 (BMP6); the pre-active MSCs can efficiently induce the acute myeloid leukemia cell differentiation, and the capacity is achieved by changing the expression quantity of IL-6 and IDO of the UC-MSCs; and the mesenchymal stem cells are allogeneic mesenchymal stem cells, the secretion capacity of the mesenchymalstem cells can be remarkably changed after the mesenchymal stem cells are treated and activated by the BMP6, and the AML resistance of the mesenchymal stem cells is remarkably enhanced. Compared withchemotherapy, mesenchymal stem cell transplantation has lower toxic and side effects, has low immunogenicity and meets clinical requirements. According to the method, the capacity of the MSCs in inducing the acute myelogenous leukemia cell differentiation is improved by adopting the method of pretreating and activating the MSCs through the BMP6, and the method can be applied to differentiation treatment of acute myelogenous leukemia.